INNOVEX THERAPEUTICS S.L. (ITSL) is the first Spanish Company that is focused on development of Exosomes and Extracellular Vesicles as new platforms for vaccines and diagnostic tools. The company was founded in March 2014 by researchers from the field of vesicles and exosomes and have industry experts in advisory roles. This approach is internationally protected (PCT/EP2010/070800).
INNOVEX THERAPEUTICS S.L. is a brand new Spin-off co-founded by Hernando A del Portillo and Francesc E. Borrás, with 10% accionary participation of three Research Institutions: Institució Catalana de Recerca i Estudis Avançats, Institute for Biomedical Research “Germans Trias i Pujol” and Instituto de salud Global Barcelona (IS Global).